title: Mechanisms of hormonal therapy resistance in breast cancer.
abstract: Whilst estrogen receptor (ER)-positive breast cancers are preferentially treated with hormone therapy, approximately one-third of them relapse. The mechanisms of refractoriness have been investigated by numerous studies but have not been fully clarified. Hormonal therapy resistance, particularly aromatase inhibitor (AI) resistance, may be related to the acquisition of alternative intracellular ER signaling. We have been investing the mechanisms using cancer specimens and cell lines by monitoring the transcription activity of ERs. AI refractory specimens showed diverse ER activity in the adenovirus estrogen receptor element-green fluorescent protein (ERE-GFP) assay and varied sensitivity to anti-estrogens, indicating the existence of multiple resistant mechanisms. We established six different types of cell lines mimicking AI resistance from ERE-GFP-introduced ER-positive cell lines. They revealed that multiple and alternative ER activating pathways were involved in the resistance, such as phosphorylation-dependent or androgen metabolite-dependent mechanisms. The response to fulvestrant and mammalian target of rapamycin inhibitor also varied among individual resistant cell lines. These results indicate that further subclassification of ER-positive breast cancer is extremely important to decide the therapeutic management of not only hormonal therapy but also new molecular target therapy.
authors: Department of Molecular and Functional Dynamics, and Center for Regulatory Epigenomics and Diseases, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Japan, shin@med.tohoku.ac.jp.
authors: Shin-ichi
authors: S
authors: Hayashi
authors: Mariko
authors: M
authors: Kimura
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008024:Ligands; D010766:Phosphorylation; D011960:Receptors, Estrogen / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D014158:Transcription, Genetic
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D008024:Ligands; D011960:Receptors, Estrogen
references: Breast Cancer Res. 2014 Jan 23;16(1):201
references: 25192370
references: Am Soc Clin Oncol Educ Book. 2013;:null
references: 23714450
references: J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:513-22
references: 25178713
references: Endocr Relat Cancer. 2008 Jun;15(2):451-63
references: 18508998
references: N Engl J Med. 2012 Feb 9;366(6):520-9
references: 22149876
references: Ann Oncol. 2014 Dec;25(12 ):2357-62
references: 25231953
references: Cancer Res. 2005 May 1;65(9):3903-10
references: 15867390
references: Breast Cancer Res Treat. 2013 Jun;139(3):731-40
references: 23780684
references: Nat Rev Cancer. 2009 Sep;9(9):631-43
references: 19701242
references: Breast Cancer Res Treat. 2014 Jan;143(1):69-80
references: 24292869
references: Nat Rev Clin Oncol. 2013 Apr;10(4):191-210
references: 23459626
references: Cancer. 2003 Nov 1;98(9):1802-10
references: 14584060
references: Am Soc Clin Oncol Educ Book. 2013;:null
references: 23714448
references: Breast Cancer (Dove Med Press). 2014 Aug 04;6:123-33
references: 25177151
references: Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S75-84
references: 16113101
references: Cancer Res. 2005 Jun 1;65(11):4653-62
references: 15930283
references: Cancer Med. 2012 Dec;1(3):328-37
references: 23342282
references: J Steroid Biochem Mol Biol. 2014 Jan;139:61-72
references: 24128438
references: J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):265-74
references: 14623520
references: Breast Cancer Res Treat. 2014 Aug;146(3):669-73
references: 25017612
references: J Biol Chem. 2001 Mar 30;276(13):9817-24
references: 11139588
references: Breast Cancer Res. 2005;7(5):R753-64
references: 16168121
references: Cancer Lett. 2007 Oct 18;256(1):1-24
references: 17475399
references: Adv Exp Med Biol. 2008;630:19-34
references: 18637482
references: J Clin Oncol. 2005 Mar 10;23(8):1751-9
references: 15755983
references: Biochem J. 1997 Aug 15;326 ( Pt 1):149-57
references: 9337862
references: J Natl Cancer Inst. 2014 Jan;106(1):djt337
references: 24317176